1-5 of 5
Anna Ma
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

CTX110 Allogeneic CRISPR-Cas9-Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study

Joseph P. McGuirk, Constantine S. Tam, Nicolaus Kröger, Peter A. Riedell, Hemant S. Murthy, Phoebe Joy Ho, Joseph E. Maakaron, Edmund K. Waller, Farrukh T. Awan, Paul J. Shaughnessy, Armin Ghobadi, Michael R. Bishop, Ana Alfonso-Pierola, Michael Dickinson, Praveen Ramakrishnan Geethakumari, Ainsley Ross, William Stevens, Huansheng Xu, Anna Ma, Sarah Beaussant Cohen, Richard T. Maziarz, Carlos Bachier
Journal: Blood
Blood (2022) 140 (Supplement 1): 10303–10306.
https://doi.org/10.1182/blood-2022-166432
Published: 2022
Journal Articles

Objective Responses Achieved in Patients with MYC-Altered Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with the Dual PI3K and HDAC Inhibitor CUDC-907

Daniel J. Landsburg, MD, Rod Ramchandren, MD, Yasuhiro Oki, MD, John M. Pagel, MD PhD, P.J. Lugtenburg, MD PhD, Robert Gharavi, PharmD, Anna Ma, MS, Amir Hafeez, MD, Stefan Klaus Barta, MDMRCP,MS
Journal: Blood
Blood (2017) 130 (Supplement 1): 1555.
https://doi.org/10.1182/blood.V130.Suppl_1.1555.1555
Published: 2017
Journal Articles

Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of CUDC-907 in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Including Patients with MYC Alterations

Daniel J. Landsburg, MD, Radhakrishnan Ramchandren, MD, Amir Hafeez, MD, Robert Gharavi, PharmD, Tania Chander, PharmD, Anna Ma, MS, Micah M. Burch, MD, Yasuhiro Oki, MD
Journal: Blood
Blood (2016) 128 (22): 5422.
https://doi.org/10.1182/blood.V128.22.5422.5422
Published: 2016
Journal Articles

Phase 1 Trial Testing Single Agent CUDC-907, a Novel, Oral Dual Inhibitor of Histone Deacetylase (HDAC) and PI3K: Initial Assessment of Patients with Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL), Including Double Expressor (DE) Lymphoma

Anas Younes, MD, Jesus G. Berdeja, MD, Manish R. Patel, MD, Kevin R. Kelly, MD PhD, Ian W. Flinn, MD PhD, John F Gerecitano, MD PhD, Sattva S. Neelapu, MD, Amanda R. Copeland, RN, MSN, CNS, Amy Akins, RN, BSN, CCRC, Myles Clancy, Anna Ma, MS, Kaiming Sun, PhD, Ze Tian, PhD, Jing Wang, PhD, Jaye Viner, MD MPH, Yasuhiro Oki, MD
Journal: Blood
Blood (2015) 126 (23): 257.
https://doi.org/10.1182/blood.V126.23.257.257
Published: 2015
Journal Articles

CUDC-907, a Dual HDAC and PI3K Inhibitor, Potentially Targets Cancer Cells and The Microenvironment In Hematological Malignancies

Jing Wang, PhD, Natalie Pursell, PhD, Anna Ma, Ruzanna Atoyan, Maria Samson, Mylissa Borek, Steven DellaRocca, Ling Yin, Da-gong Wang, Brian Zifcak, Guang-xin Xu, Maurizio Voi, MD, Cheng-Jung Lai, PhD
Journal: Blood
Blood (2013) 122 (21): 4930.
https://doi.org/10.1182/blood.V122.21.4930.4930
Published: 2013